Online inquiry

IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1222MR)

This product GTTS-WQ1222MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TPBG gene. The antibody can be applied in Renal Cell Carcinoma (RCC), Non-small lung carcinoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001166392.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7162
UniProt ID Q13641
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1222MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15434MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ15193MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ3192MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ12481MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ9286MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-132
GTTS-WQ9953MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KBSA301
GTTS-WQ1030MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ10292MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LGT209
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW